Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With

Timothy L Cannon; Michael Rothe; Pam K Mangat; Elizabeth Garrett-Mayer; Vi K Chiu; Jimmy Hwang; Namrata Vijayvergia; Olatunji B Alese; Elie G Dib; Herbert L Duvivier; Kelsey A Klute; Vaibhav Sahai; Eugene R Ahn; Pablo Bedano; Deepti Behl; Sarah Sinclair; Ramya Thota; Walter Urba; Eddy S Yang; Gina N Grantham; Dominique C Hinshaw; Abigail Gregory; Susan Halabi; Richard L Schilsky

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With

Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu, Jimmy Hwang, Namrata Vijayvergia, Olatunji B Alese, Elie G Dib, Herbert L Duvivier, Kelsey A Klute, Vaibhav Sahai, Eugene R Ahn, Pablo Bedano, Deepti Behl, Sarah Sinclair, Ramya Thota, Walter Urba, Eddy S Yang, Gina N GranthamDominique C Hinshaw, Abigail Gregory, Susan Halabi, Richard L Schilsky

Research output: Contribution to journal › Article

Abstract

PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with

METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with

RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an

CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and

Original language	Undefined/Unknown
Journal	Articles, Abstracts, and Reports
State	Published - May 15 2024

Access to Document

http://digitalcommons.providence.org/publications/8864

Cite this

Cannon, T. L., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Chiu, V. K., Hwang, J., Vijayvergia, N., Alese, O. B., Dib, E. G., Duvivier, H. L., Klute, K. A., Sahai, V., Ahn, E. R., Bedano, P., Behl, D., Sinclair, S., Thota, R., Urba, W., Yang, E. S., ... Schilsky, R. L. (2024). Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With. Articles, Abstracts, and Reports. http://digitalcommons.providence.org/publications/8864

@article{e11bb12e0d1b4aa8b2d9612b4092631e,

title = "Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With",

abstract = "PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and",

author = "Cannon, {Timothy L} and Michael Rothe and Mangat, {Pam K} and Elizabeth Garrett-Mayer and Chiu, {Vi K} and Jimmy Hwang and Namrata Vijayvergia and Alese, {Olatunji B} and Dib, {Elie G} and Duvivier, {Herbert L} and Klute, {Kelsey A} and Vaibhav Sahai and Ahn, {Eugene R} and Pablo Bedano and Deepti Behl and Sarah Sinclair and Ramya Thota and Walter Urba and Yang, {Eddy S} and Grantham, {Gina N} and Hinshaw, {Dominique C} and Abigail Gregory and Susan Halabi and Schilsky, {Richard L}",

year = "2024",

month = may,

day = "15",

language = "Undefined/Unknown",

journal = "Articles, Abstracts, and Reports",

}

Cannon, TL, Rothe, M, Mangat, PK, Garrett-Mayer, E, Chiu, VK, Hwang, J, Vijayvergia, N, Alese, OB, Dib, EG, Duvivier, HL, Klute, KA, Sahai, V, Ahn, ER, Bedano, P, Behl, D, Sinclair, S, Thota, R, Urba, W, Yang, ES, Grantham, GN, Hinshaw, DC, Gregory, A, Halabi, S & Schilsky, RL 2024, 'Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With', Articles, Abstracts, and Reports. <http://digitalcommons.providence.org/publications/8864>

TY - JOUR

T1 - Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With

AU - Cannon, Timothy L

AU - Rothe, Michael

AU - Mangat, Pam K

AU - Garrett-Mayer, Elizabeth

AU - Chiu, Vi K

AU - Hwang, Jimmy

AU - Vijayvergia, Namrata

AU - Alese, Olatunji B

AU - Dib, Elie G

AU - Duvivier, Herbert L

AU - Klute, Kelsey A

AU - Sahai, Vaibhav

AU - Ahn, Eugene R

AU - Bedano, Pablo

AU - Behl, Deepti

AU - Sinclair, Sarah

AU - Thota, Ramya

AU - Urba, Walter

AU - Yang, Eddy S

AU - Grantham, Gina N

AU - Hinshaw, Dominique C

AU - Gregory, Abigail

AU - Halabi, Susan

AU - Schilsky, Richard L

PY - 2024/5/15

Y1 - 2024/5/15

N2 - PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and

AB - PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and

M3 - Article

JO - Articles, Abstracts, and Reports

JF - Articles, Abstracts, and Reports

ER -